SCIOS INC
DFAN14A, 2000-01-24
PHARMACEUTICAL PREPARATIONS
Previous: SCIOS INC, 8-K, 2000-01-24
Next: SCIOS INC, DFAN14A, 2000-01-24



                                SCHEDULE 14A
                               (RULE 14A-101)
                          SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934
                           (AMENDMENT NO.      )

 Filed by the Registrant {  }
 Filed by a Party other than the Registrant {X}

 Check the appropriate box:

 { }   Preliminary Proxy Statement
 { }   Confidential, For Use of the Commission Only (as permitted by
       Rule 14a-6(e)(2))
 { }   Definitive Proxy Statement
 {X}   Definitive Additional Materials
 { }   Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12

                                 SCIOS INC.
    -------------------------------------------------------------------
              (Name of Registrant as specified in its charter)

                               RANDAL J. KIRK
                                RJK, L.L.C.
                             KIRKFIELD, L.L.C.
                      THE KIRK FAMILY INVESTMENT PLAN
   ---------------------------------------------------------------------
    (Name of person(s) filing proxy statement, if other than Registrant)


 Payment of Filing  Fee (Check the appropriate box):

 {X}  No fee required.

 { }  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-
      11.

      (1)  Title of each class of securities to which transaction applies:
      (2)  Aggregate number of securities to which transaction applies:
      (3)  Per unit price or other underlying value of transaction computed
           pursuant to Exchange Act Rule 0-11:
      (4)  Proposed maximum aggregate value of transactions:
      (5)  Total fee paid.

 _________
 {  } Fee paid previously with preliminary materials.
 {  } Check box if any part of the fee is offset as provided by Exchange Act
      Rule 0-11(a)(2) and identify the filing for which the offsetting fee
      was paid previously.  Identify the previous filing by registration
      statement number, or the Form or Schedule and the date of its filing.

      (1)  Amount Previously Paid:
      (2)  Form, Schedule or Registration Statement No.:
      (3)  Filing Party:
      (4)  Date Filed:


                               PRESS RELEASE


 Media Contact:      Caroline Gentile/Robert Siegfried
                     Kekst and Company
                     212-521-4800

 Investor Contact:   Corporate Investor Communications
                     877-842-2404

                  RANDAL J. KIRK, MAJOR SCIOS STOCKHOLDER,
                PREPARED TO MEET WITH SCIOS BOARD FORTHWITH

        -- URGES SCIOS TO BE CONCERNED WITH STOCKHOLDER VALUE RATHER
        THAN THE HYPING OF THE 'CREDENTIALS OF ITS BOARD MEMBERS --

 RADFORD, VA,  JANUARY 20, 2000 -- Randal J. Kirk, a major stockholder of
 Scios Inc. (NASDAQ: SCIO), today stated, "In response to my proposal to
 build Scios stockholder value, both over the immediate-and-long-term, I am
 pleased that the Scios Board has accepted my offer to meet and has
 committed, according to its own communications to stockholders, to do so
 'as soon a meeting can be arranged'.  For my part, I am prepared and
 available to meet immediately with the Scios Board so that, working
 together, there can be in place, for a change, a bona fide feasible plan to
 achieve stockholder value at Scios.  There is absolutely no reason, if the
 Scios Board is really sincere, that such a meeting cannot be arranged
 forthwith.

 "I am not surprised at the attempted public relations spin by Scios'
 Chairman Donald Rice and its CEO Richard Brewer that the incumbent Scios
 Board should be re-elected over the slate of nominees I am proposing
 because of its 'impressive credentials', which are debatable.  The fact is,
 that, under this ostensibly stellar Board, Scios' stock trades in the $5.00
 range, has lost approximately 58% of its market value since last May, and
 has failed to commercialize a single product, including Natrecor, for which
 it failed to obtain FDA approval last Spring.

 "I do find it odd, however, that Scios' Board finds it necessary 'to spend
 corporate assets' to 'protect' its stockholders against my actions, given
 my good-faith offer to meet with them and reach a compromise.  All I seek
 from my compromise offer is to create stockholder value for all of Scios'
 stockholders and to be assured that such a compromise will be carried out
 through minority Board representation.  It is a board's duty to serve its
 stockholders and act in their best interest.  Given this Board's treatment
 of me, as Scios' largest stockholder, I question whether this Board is
 fulfilling its duty.

 "I hope that the meeting will be about performance and not about the
 supposedly illustrious pasts of the incumbent Board and I shall attend the
 meeting with the expectation that the Board is ready to talk seriously
 about how to unlock the currently hidden value of Scios.  The company has
 such outstanding potential but the current share price proves that that
 potential is not being realized under any currently active management
 plan," Mr. Kirk said.




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission